Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pullarkat, Vinod
NCT04747613: Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria	Recruiting	3	250	Europe, Japan, US, RoW	Iptacopan, LNP023	Novartis Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria	10/27	10/27
NCT04284228: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT	Active, not recruiting	1/2	22	US	Infusion of NEXI-001 T Cells	NexImmune Inc.	Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)	10/24	03/25
NCT04810611: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS	Terminated	1	33	Europe, US, RoW	MBG453, sabatolimab, NIS793, canakinumab, ACZ885	Novartis Pharmaceuticals	Myelodysplastic Syndromes	04/24	04/24
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies	Recruiting	1	36	US	DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto	Kahr Medical	Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia	06/25	06/25